AI Article Synopsis
- Antipsychotics can lead to weight gain in patients with schizophrenia, and this phenomenon may have a genetic component.
- A study involving 139 patients identified the HTR1D rs6300 genetic polymorphism, which may imply some risk for obesity, although it wasn't statistically significant after multiple testing.
- Clinical factors, including ethnicity and the type of antipsychotic medication (like olanzapine and haloperidol), were more strongly associated with the risk of significant weight gain, highlighting the need to understand different patient subgroups.
Article Abstract
Antipsychotics-induced weight gain is a complex phenomenon with a relevant underlying genetic basis. Polymorphisms of serotonin receptors and related proteins were genotyped in 139 schizophrenia patients and incorporated as covariates in a mixture regression model of weight gain in combination with clinical covariates. The HTR1D rs6300 polymorphism was showing a slight significance conferring risk for obesity (heavy weight gain group) under additive model. After correcting for multiple testing all the genetic predictors were non-significant, however the clinical predictors were associated with the risk of heavy weight gain. These findings suggest a role of ethnicity and olanzapine in increasing the risk for obesity in the heavy weight gain group and haloperidol protecting against heavy weight gain. The mixture regression model appears to be a useful strategy to highlight different weight gain subgroups that are affected differently by clinical and genetic predictors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euroneuro.2012.05.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting ultra-processed foods for prevention of type 2 diabetes: state of the evidence and future directions.
Diabetologia
January 2025
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
The incidence of type 2 diabetes has risen globally, in parallel with the obesity epidemic and environments promoting a sedentary lifestyle and low-quality diet. There has been scrutiny of ultra-processed foods (UPFs) as a driver of type 2 diabetes, underscored by their increasing availability and intake worldwide, across countries of all incomes. This narrative review addresses the accumulated evidence from investigations of the trends in UPF consumption and the relationship with type 2 diabetes incidence.
View Article and Find Full Text PDFMethods for modeling gestational weight gain: empirical application using electronic health record data from a safety net population.
BMC Pregnancy Childbirth
January 2025
Oregon Health & Science University-Portland State University School of Public Health, Portland, OR, USA.
Background: Understanding the risks and effects of gestational weight gain (GWG) is a prominent area of perinatal research but approaches for quantifying GWG are evolving and remain underdeveloped, especially in clinical settings for underserved demographic subgroups. To fill this gap, we demonstrated and compared six GWG metrics across pre-pregnancy BMI classifications: total GWG, trimester-specific linear rate of GWG, adherence to total and trimester-specific recommendations, area under the curve, and GWG for gestational age z-scores.
Methods: We used clinical data on 44,801 pregnant people from community-based health care organizations with extensive longitudinal measures and substantial representation of understudied subgroups.
The (dys)regulation of energy storage in obesity.
Physiol Rev
January 2025
University of Zurich, Vetsuise Faculty, Institute of Veterinary Physiology, Zurich, Switzerland.
Metabolic energy stored mainly as adipose tissue is homeostatically regulated. There is strong evidence that human body weight () is physiologically regulated, i.e.
View Article and Find Full Text PDFPan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.
J Hepatol
January 2025
Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida, United States of America. Electronic address:
Background & Aims: Lanifibranor is a pan-PPAR agonist that improves glucose/lipid metabolism and reverses steatohepatitis and fibrosis in adults with MASH. We tested its effect on insulin resistance at the level of different target tissues in relationship to change in intrahepatic triglyceride (IHTG) content.
Methods: This phase 2, single center, study randomized (1:1) 38 patients with T2D and MASLD to receive lanifibranor 800 mg or placebo for 24 weeks.
Detection of necrotic enteritis risk through non-invasive monitoring of Clostridium perfringens in feces.
Poult Sci
January 2025
Ancera, Inc, Branford, CT 06405, USA. Electronic address:
Necrotic enteritis (NE), caused by the gram-positive, anaerobic bacterium, Clostridium perfringens, results in an estimated $6 billion in annual economic losses to the global poultry industry. C. perfringens is part of the normal microflora of the poultry gastrointestinal tract, but damage to the intestinal epithelium can lead to increased cell proliferation and production of toxins which gives rise to disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!